Franchini Massimo, Marano Giuseppe, Pupella Simonetta, Vaglio Stefania, Masiello Francesca, Veropalumbo Eva, Piccinini Vanessa, Pati Ilaria, Catalano Liviana, Liumbruno Giancarlo Maria
Italian National Blood Centre, National Institute of Health, Rome, Italy.
Department of Haematology and Transfusion Medicine, Carlo Poma Hospital, Mantua, Italy.
Ann Transl Med. 2018 Sep;6(17):331. doi: 10.21037/atm.2018.08.34.
The rare congenital bleeding disorders are a heterogeneous group of diseases which include deficiencies of fibrinogen, prothrombin and factors V, V + VIII, VII, X, XI and XIII. They are usually transmitted as autosomal recessive disorders, and the prevalence of the severe forms ranges from one case in 500,000 for factor VII up to one in 2,000,000 for factor XIII in the general population. Patients with rare congenital bleeding disorders may have a broad spectrum of clinical symptoms, ranging from mucocutaneous bleeding to life-threatening haemorrhages, such as those occurring in the central nervous system. The treatment of these disorders is based principally on the replacement of the deficient factor using, when available, specific plasma-derived or recombinant products. The aim of this narrative review is to summarise current knowledge about these rare bleeding conditions.
罕见先天性出血性疾病是一组异质性疾病,包括纤维蛋白原、凝血酶原以及Ⅴ、Ⅴ + Ⅷ、Ⅶ、Ⅹ、Ⅺ和ⅩⅢ因子缺乏。它们通常以常染色体隐性疾病形式遗传,在普通人群中,严重型疾病的患病率从Ⅶ因子的50万分之一到ⅩⅢ因子的200万分之一不等。患有罕见先天性出血性疾病的患者可能有广泛的临床症状,从皮肤黏膜出血到危及生命的出血,如发生在中枢神经系统的出血。这些疾病的治疗主要基于使用特定的血浆来源或重组产品替代缺乏的因子(如有可用产品)。本叙述性综述的目的是总结关于这些罕见出血性疾病的现有知识。